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AIM / OBJECTIVES   :  
 
 
To study the patients who required surgical resection for treatment of Bronchiectasis 
in our institution over the last 21 years (1992-2012).  
Demographic details, mode of presentation, investigations done, surgical details, 
morbidity, and mortality and long term surgical outcome are studied.  
 
 
 
MATERIAL AND METHODS 
 
 We analyzed the patient details retrospectively using the charts as well as our 
clininical work station. Categorical data were expressed as frequency & percentage. 
Continuous   variable expressed as mean ± standard deviation or median and range. 
Significant differences between proportions determined by chi-squared analysis Or Fisher’s 
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exact test. All analyses were carried out using Statistical Package for Social Sciences version 
11.5 (SPSS, Inc., Chicago, IL, USA). Probability values p < 0.05 were considered significant 
  
 
 
RESULTS 
 
  
We had a total of 242 patients in our series from 1992-2012.Bronchiectasis is more 
common in males (64%). Commonly it involves left side. Patient opts for surgery because of 
failed medical treatment. Hemoptysis is the common indication (45%) for surgery. More than 
half (65%) of the patients have typical features of Bronchiectasis in the X-ray itself. HRCT 
was done before surgery for all patients, which is considered as the imaging of choice. Most 
of our patients had restrictive PFT (56%). Sputum had grown some organisms in 57% of our 
patients. Majority of our patients were operated for Hemoptysis (48%). Common procedure 
done for our patients was single Lobectomy (54.5%). There were 39 patients who had 
complications in our series. There was statistically significant association between pre-op 
cultures, preop PFT and extent of disease to the post operative outcome. Complete resection 
of the disease is single most important criteria for prevention of post-operative symptoms 
however bilateral diffuse disease shall remain to have post-op minimal symptoms. There 
were two mortality in our series. 
 
 
 
CONCLUSIONS 
  
Bronchiectasis is primarily a medical disease which requires careful assessment and 
diagnosis. Once diagnosis is made, the patient should be under medical surveillance and 
treatment for repeated infections and haemoptysis.  Appropriate antibiotics as dictated by 
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cultures should be initiated in order to avoid progression of the disease. If and when surgery 
is indicated, a thorough pre-operative evaluation should be carried out.    As in other 
literature, our study also proves that surgical treatment for Bronchiectasis can be done safely 
with minimal acceptable mortality and morbidity. Single most important factor which decides 
on the symptom free state after surgery is the adequacy of the resection. Complete resection 
of the localised Bronchiectasis offers better cure as well as symptom free survival after 
surgery. However it should be appreciated that in cases of diffuse bilateral disease, post 
operative residual Bronchiectasis is unavoidable. In such cases, though the intensity of 
symptoms may improve greatly after surgery, minimal symptoms may persist.   
 
Key words  
Bronchiectasis surgical management, post-operative complication, residual 
Bronchiectasis . 
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INTRODUCTION 
Bronchiectasis is chronic respiratory disease which has a got long duration of 
symptoms, varied clinical presentation and numerous methods of management. It is primarily 
a medical disease which requires careful follow up, once the medical treatment becomes 
ineffective the patient is offered surgical treatment. The exact incidence of this disease is 
difficult to estimate because most of the studies in the literature are based on radiological 
investigations and treatment was offered to the patient coming to hospital. The burden of this 
disease in the community level especially in developing countries is more than the estimated 
figure. The surgical treatment for Bronchiectasis in the previous era was pneumonectomy,  
but the concept of lung parenchymal preservation lead to lobectomies. The various 
procedures for Bronchiectasis includes lobectomy, bilobectomy, segmentectomy alone or 
together with lobectomy and pneumonectomy. The surgical treatment in Bronchiectasis can 
be safely performed with acceptable morbidity and mortality.  
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AIMS 
To study the patients who required surgical resection for treatment of Bronchiectasis 
in our institution over the last 21 years (1992-2012).  
Demographic details, mode of presentation, investigations done, surgical details, 
morbidity, and mortality and long term surgical outcome are studied.  
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OBJECTIVES 
 
The objective of our study was to analyse the patient demographics ,mode of 
presentation, investigation, type of surgery performed  in relation to post-operative outcome 
in terms of complete relief of symptoms or persistence of minimal symptoms. 
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MATERIALS AND METHODS 
The records of all patients who underwent surgical treatment for Bronchiectasis at our 
institution between January 1992 and December 2012 were retrieved. The demographic 
details of the patient, the mode of presentation, indication for surgery, pre-operative 
investigations like sputum culture , X-ray, Computerised Tomography, type of surgery 
offered, post operative complications, follow up of the patient were studied in detail.  
Statistical analysis of the data was performed using the chi- square test, paired T test, 
frequency and percentages. All p-values were two tailed and a value of less than 0.05 was 
considered significant. 
 
SURGICAL TECHNIQUE 
 All patients received prophylactic antibiotics of Inj. Ceftazidime 30-50 mg/kg/day 
and Inj. Augumentin 15  mg/kg at the time of induction and followed by Inj. Ceftazidime 30-
50 mg/kg/day in divided doses for two more days and oral Augumentin 25mg/kg for 5 days. 
All the patients were subjected to Double lumen Tube (DLT) intubation for favour of 
isolation of the lung. A standard posterolateral thoracotomy with or without cutting serratus 
anterior muscle was performed for all cases. After the desired procedure patients were 
extubated on table and shifted to post-operative ward. After single day observation patients 
are transferred to ward unless warranted.   
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FOLLOW UP 
Retrospective analysis of the hospital records were used to study the follow up data of  
patients . During the follow up period the symptoms were analysed, X ray was taken as a 
routine for all patients who come for follow up. In patient who were symptomatic High 
resolution Computerised Tomography was taken.  
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REVIEW OF LITERATURE 
Definition of Bronchiectasis 
Bronchiectasis (bronchus-tube, ectasis-to stretch) is a chronic respiratory condition 
which is characterized by abnormal permanent dilation of the bronchi. Bronchiectasis, as 
described Reid in 1999 as a permanent dilatation of bronchi with destruction of bronchial 
wall, holds good even today. It is caused by destruction of the elastic and muscular 
components of the bronchial walls.  With the advent of antibiotics the incidence of 
Bronchiectasis has declined in developed nations, but in developing countries it still causes 
significant morbidity and mortality (1). Ironically, even in a well developed country like USA 
the burden of the disease is steadily increasing in the current decade when compared to the 
earlier  decades(2). 
 
Epidemiology 
 It is not easy to estimate the prevalence of this disease in any particular geographical 
area in the past, since most of the literatures in the earlier times were based on chest X-ray 
findings only. Chest x-rays is not the most sensitive tool for diagnosing Bronchiectasis.  
 
With the evolution of High Resolution Computed Tomography (HRCT)  it is 
observed that even in persons undergoing  investigation for unrelated respiratory diseases like  
Chronic Obstructive Pulmonary disease (COPD) and bronchial asthma and even in smokers 
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with chronic bronchitis there is incidental diagnosis of Bronchiectasis, hence it’s obvious that 
the   prevalence of the disease tends to be underestimated. 
  
Certain ethnic groups like native North Americans, Western and Maoris of New 
Zealand have high incidence of the disease either due to genetic factors or due to 
environmental factors. The exact prevalence in a population can only be obtained with the 
availability of a cheap, widely applicable yet accurate imaging technique. 
 
Types of Bronchiectasis  
1. Cystic or saccular type  
     Bronchial wall is dilated like balloon. 
     Usually seen in children due to repeated viral or bacterial infection. 
2. Cylindrical type 
     Cylindrical dilatation due to lesser degree of damage. 
     It is often diffuse and affects lower lobes commonly 
3. Varicose type 
    Areas of stenosis and constrictions in dilated bronchi 
4. Traction Bronchiectasis 
   Usually occurs in setting of pulmonary fibrosis. 
   Fibrosis causes traction on the bronchial wall. 
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Aetiology 
There are numerous known causes of Bronchiectasis, yet in half of the patient the 
cause may not be known. Bronchiectasis may be congenital or acquired. In congenital 
Bronchiectasis, the bronchial tree is diffusely involved, whereas when acquired due to 
infection, it tends to be localized. The following causes, adapted from Barker et al(3) 
summarizes the various etiologic factors for Bronchiectasis . 
The underlying common mechanism for development of Bronchiectasis is recurrent, 
transmural infection and inflammation of the bronchial wall. 
 
Aetiology 
Congenital causes 
Acquired causes 
   Infections   
                     Inhalation of toxins 
    Foreign body aspiration 
     Connective tissue disorders 
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Infection  
Bronchiectasis can be caused by bacterial, viral or fungal infections. Repeated 
infections destroy the wall of the bronchus causing the disease.   Bronchiectasis in childhood 
used to be a common complication of measles or pertussis in the past, but effective 
vaccination has decreased the prevalence of the disease even in developing countries.  
 
Currently, adeno and influenza viruses are associated with the development of 
Bronchiectasis in children. Organisms like S. aureus, K.pneumoniae, H. influenzae, and 
anaerobes are also important causes of Bronchiectasis. It is an interesting observation that 
whenever appropriate antibiotic treatment is delayed or deferred while treating the common 
causative pathogens of Bronchiectasis, there is a propensity for the same bronchi to be by 
repeated infection which ultimately leads to Bronchiectasis of that area. .  
 
In 64% of patients with Bronchiectasis there is presence of potentially pathogenic 
bacteria (PPM). Common PPMs include H. influenzae, Pseudomonas spp, and S. Pneumonia.  
Varicose  or saccular Bronchiectasis are  risk factors for such colonisations(3). Human 
immune deficiency virus (HIV) affected patients in their later stages develop Bronchiectasis 
due to repeated infections. 
 
Tuberculosis (TB) remains an important cause of Bronchiectasis in underdeveloped 
countries. In developing countries tuberculosis is endemic. Together with poor hygiene and 
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overcrowding it is a major cause of cause of Bronchiectasis(4).The prognosis becomes worse 
if atypical Mycobacterium are involved.  
 
 
Mechanical obstructive causes 
The obstruction to the bronchi can be either intra luminal or extra luminal. Main 
causes for intra luminal obstruction are foreign bodies and neoplasm. Extrinsic compression 
is usually due to enlarged lymph nodes around the bronchi. The mechanisms for development 
of Bronchiectasis are  
 
1. Impaired clearance of the secretions resulting in repeated 
infections leading to damage to bronchial wall 
2. The negative intra pleural pressure along with atelectasis causes       
centripetal pull on the bronchial wall  
 
In extremes of age, aspirations of foreign body often go unnoticed for a long time till 
symptoms develop (5). 
 
Congenital causes 
Impaired mucociliary clearance 
Cystic fibrosis   
Cystic fibrosis (CF)  is caused by a mutation. CF is caused whenever there is mutation 
in the gene cystic fibrosis trans membrane conductance regulator .  It usually involves both 
the upper lobes. The thick secretions in cystic fibrosis interfere with effective mucociliary 
clearance thus making the individual prone for recurrent infections leading to Bronchiectasis. 
They often develop opportunistic infections,  usually pseudomonas aeruginosa which 
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becomes chronic and makes the individual prone for Bronchiectasis(6).   Milder mutations of 
cystic fibrosis may present as late onset Bronchiectasis. 
 
 
Primary ciliary dyskinesia 
Primary ciliary dyskinesia is an autosomal recessive disorder, here the cilia have ultra 
structural abnormalities. Abnormal micro tubules, absence of one or both dyenin arms, 
abnormal radial spokes are the common abnormalities making the cilia immotile, or beat in 
disorderly fashion, thereby hampering mucus clearance.           
             
Ciliary dysmotility syndromes 
Here the cilia are dyskinetic and hence the muco-propulsive action is decreased 
leading to impairment in clearing secretions favouring bacterial colonization, eventually 
leading to infection and subsequent Bronchiectasis. There are associated syndromes  like 
Kartagener`s which includes recurrent respiratory tract infections, sinusitis, otitis media, 
bronchiectasis, situs inversus  and immotile sperm(7). 
 
Immune deficiency 
Congenital impairment in  immune  mechanisms is  another important cause of 
Bronchiectasis as seen with immunoglobulin deficiencies including panhypogamma 
globulinemia, IgG subclass deficiency and selective IgA deficiency (7). Immune mechanisms 
should be suspected in patients with recurrent acute episodes rather than chronic infection. 
IgA deficiency occurs in 0.1%-0.2% of general population. IgG subclass deficiency like IgG2 
is associated with recurrent pneumococcus pneumonia. An acquired immunodeficient state is 
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noted in individuals suffering from lymphoma, leukaemia and multiple myeloma. In such 
patients, recurrent infections can lead to cylindrical Bronchiectasis.  
 
 
 
Non-infective- inflammatory causes 
 Inhalation of toxic gases such as ammonia, chlorine or smoke can cause the 
inflammation in bronchial mucosa. It basically causes obliterative bronchiolitis. This, 
together with damage to the walls of the larger bronchi can cause cylindrical Bronchiectasis. 
Aspiration of gastric contents triggers severe inflammatory responses leading to bronchial 
wall destruction leading to Bronchiectasis. 
 
Immune mediated causes 
In allergic bronchopulmonary aspergillosis, there is an immune response to colonized 
Aspergillus organisms which in association with asthma can lead to  cylindrical 
Bronchiectasis (8). 
 
Bronchiectasis can also occur in other immunologic diseases like ulcerative colitis(9), 
rheumatoid arthritis and Sjogren's syndrome. Alpha 1 Antitrypsin, deficiency, in which early 
onset and severe pan-acinar emphysema is the usual manifestation, may also be accompanied 
by Bronchiectasis (10). 
 
 Alpha-1 antitrypsin deficiency is associated with increased incidence of  chronic 
obstructive pulmonary disease (COPD) and Bronchiectasis (11). 
 
Non tuberculous Mycobacterium (NTM) and Bronchiectasis 
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Mycobacterium Avium intracellulare complex and mycobacterium kansasii are 
known to cause progressive Bronchiectasis that is limited to middle lobe and lingula. It 
typically involves healthy, non-smoking, thinly built women resulting in the so called Lady 
Windermere syndrome (12). 
 
Pulmonary fibrosis 
Fibrosis of due to causes like sarcoidosis, radiation, cryptogenic fibrosing alveolitis 
could also lead to Bronchiectasis.  
 
Pathophysiology  
Cole’s “vicious cycle hypothesis” says that environmental insult with genetic 
susceptibility combined with decreased muco-ciliary clearance results in persisting  microbes 
in the sinobronchial tree and microbial colonization, results in tissue damage and decreased 
mucociliary motility.  This leads to more infection with a cycle of progressive inflammation 
causing lung damage. The current view is that the two factors required for the development of 
this condition are persistent infection and a defect in host defence(13). 
 
The inflammatory changes in the walls of bronchi in medium-sized airways lead to 
the destruction of normal structural components of the wall, including cartilage, muscle, and 
elastic tissue, which are replaced by fibrous tissue. Bronchial wall is destroyed by  proteases 
released predominantly by neutrophils, which damages large airways leading to bronchial 
dilatation(14). Finally the inflammation spreads beyond airways to cause interstitial 
pneumonia. Recent investigations have also proved that lymphoid aggregates in chronic 
obstructive pulmonary disease (COPD)  patients also cause bronchial thickening (15).  As 
with other infections, dominant cells of inflammation in Bronchiectasis are neutrophils, 
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macrophages and lymphocytes. Neutrophils are the main source of proteases (16). Adjacent 
parenchyma is also involved in the inflammation and may lead to localized  emphysema(17). 
The dilated airways are commonly filled with pools of thick, purulent material and more 
distal airways are often occluded by secretions or obliterated by fibrous tissue. The 
parenchyma that is supplied by the affected airways is commonly abnormal, with varying 
amounts of fibrosis, emphysema, pneumonia, and atelectasis. As a result of this inflammation 
there is enhanced vascularity of the bronchial wall with enlargement of the bronchial arteries 
and abnormal anastomosis between bronchial and pulmonary arterial circulations. This is the 
principal source for haemoptysis in such patients which may require urgent angiographic or 
surgical intervention. 
 
Distribution of Bronchiectasis 
Infectious causes tend to affect the upper lobes if secondary to tuberculosis while the 
other bacterial or viral pathogens affect lower lobe. The lower lobes are more affected due to 
retention of secretions in the dependant portion of the lungs(18,19). Middle lobe gets affected 
by the disease because of its long slender bronchi with acute angulations  which gets easily 
compressed by a collar of enlarged lymph nodes(20–24). 
 
Malnutrition and socio-economic status 
Bronchiectasis is a major problem in developing nations like India(25) 
,china(26),turkey(27) , Hong Kong and in certain parts of south America(28) . Even in certain 
subset of immigrants in developed countries it is common. Malnutrition is associated with 
lowered immunity which may explain the increased prevalence in such groups. 
 
Extremes of age 
 28 
 
The immune system in childhood as well as old age seems to be less effective making 
these individuals more prone for development of the disease. Childhood infections especially 
during first few years of life with persistent infection during childhood make them 
susceptible for development of Bronchiectasis. In old age there is increase the incidence of 
COPD and subsequent development of Bronchiectasis because of repeated chronic infections. 
 
Microbiology 
The nature of bacterial flora in Bronchiectasis varies depending upon the location, 
severity of disease and duration. Studies  have shown that H.influenza followed by 
Pseudomonas aeuroginosa as common organisms (29–31) isolated from Bronchiectasis 
patients. Appearance of sputum and the growth of microorganisms from it is misleading, as 
the most purulent appearing sputum may not grow any organism(32–35). The  bacteria also 
changes its strains once in every two or three months in chronic patients(36).  In COPD 
patients its noted that during the time of acute exacerbations the bacterial flora changes  (37).  
Likewise in Bronchiectasis,  depending on the severity of disease,  the bacterial flora changes 
constantly (35). 
 
 H.influenza followed by Pseudomonas are the most commonly isolated organisms.  
H.influenza which is isolated has varying types depending on the geographical area. These 
non tuberculous micro-organisms may complicate the outcome of the patient depending on 
the immunity of the patient (38,39). 
 
Role of viral involvement in Bronchiectasis is not well dassociated unlike in 
COPD(40). However, some investigators have consistently isolated adenovirus in children 
with Bronchiectasis(41). 
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Effects of bacterial pathogens on the respiratory tract 
The bacterial colonies in the respiratory tract have direct as well as indirect effect by 
lowering the host immune response leading to damage in the ciliary epithelium. In chronic 
cases, this bacterial enzymatic reaction damages the bronchial wall, attracts the neutrophils 
which causes further damage to the epithelium, cartilage and lung parenchyma resulting in 
permanent structural damage. Certain organisms like H.influenza directly invade the  
parenchyma (42,43),whereas pseudomonas has the capacity of form a bio film around itself 
to help escape from immune mediated cells(44). 
 
Clinical features 
Patients with Bronchiectasis present with recurrent pulmonary infections manifesting 
from no symptoms to simple cough with expectoration and dyspnoea. Some patients have 
unremitting chronic cough with thick, tenacious purulent sputum. Haemoptysis is a common 
symptom with which patient may be hospitalised. It may range from streaks of blood to 
massive haemoptysis requiring urgent intervention(45). In many studies in the third world as 
well as in developing countries,  Bronchiectasis remains at the top of the list as a cause for 
haemoptysis(46–48). The source of bleeding is from the dilated tortuous peribronchial 
arteries of the affected region which erodes into lumen causing haemoptysis.  
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Auscultation reveals crackles, wheeze, rhonchi or signs of bronchospasm. 
Haemoptysis may be life threatening if source of bleeding is from the neo-vascularizied 
vessel which usually is stimulated by hypoxia and chronic airway inflammation(49,50). It is 
common in India where patients with Bronchiectasis will be having productive cough for a 
long time. After taking “over the counter” drugs for considerable time, they present to 
hospital only if there is haemoptysis. Since inception, bronchial artery embolization  has 
saved many patients from catastrophe. Initially,  spongicel was used, but this had significant 
incidences of  rebleed (51). Later, the use of coils for embolization has made dramatic 
improvement since the  recannalisation rates are low (52) . The bronchial arteries when it 
dilates due to  hypoxiemia of that region tends to develop anastamosis with pulmonary 
arterioles thus giving rise to left to right shunt.  In extreme cases,  there may be features of 
pulmonary artery hypertension when there is excessive left to right shunting(53). 
 
Diagnosis 
Any patient who presents with chronic muco-purulent sputum must be worked up for 
Bronchiectasis (54).If patients are educated to measure the sputum volume every day,  
interestingly it has co-relation with quality of life and lung function (55). Non-specific 
symptoms like malaise, fatigue, evening rise of temperature, chest pain, breathlessness on 
exertion may be present(54,56,57). Haemoptysis is an important symptom which the patient 
really worries and seeks medical attention in developing countries(58). Certain  physical 
findings like crackles , wheeze and clubbing of digits may be present in some patients(54,56). 
   A plain chest X-ray will give the diagnosis of Bronchiectasis if it is severe enough 
and shows classical honey-comb pattern(59) . There is a problem of under diagnosis with 
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these x-ray studies.  It has been demonstrated in many studies that it can diagnose only 50% 
of the cases, remaining patients require additional investigations to confirm the 
pathology(60). Tram lines or parallel lines seen along the course of bronchi in a plain chest 
X-ray indicate severe Bronchiectasis. Before the era of CT scan, bronchography was used to 
confirm the diagnosis. After the availability of  Computerised tomography this has become 
the gold standard in diagnosing Bronchiectasis especially the High Resolution Computed 
Tomography (HRCT) (55,61). Cystic type of Bronchiectasis gives shows multiple air fluid 
levels.  In cylindrical variety the dilatation appears smooth and more uniform. Varicose type 
usually little advanced type with uniform dilatation alternating with areas of constriction 
giving a beaded appearance.  
  In HRCT, the thorax is scanned twice, once during suspended inhalation  and another 
during exhalation to detect minute details and micro air trapping. Certain features in HRCT 
are almost diagnostic of the condition like: 
1) Signet ring formation where diameter of bronchi appears more than adjacent  
 pulmonary arter 
2)   Absent normal tapering of the  bronchi  
3) Unusual appearance of bronchi at the periphery (54,56,62).  
 
The findings of the HRCT is important as it has been proved in studies that it co-
relates with clinical outcomes (54,61,63). Mucus plugging along with dilated arteriole and 
aggregates of nodule appear like tree-bud in CT. With the new technological advances like 
multi detector computed tomography, it is possible to reconstruct with 3-Dimensional 
imaging and asses the airway in a better way(64,65). 
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Pulmonary function testing in these cases is useful in diagnosing the air flow 
limitation, but it does not help to identify the early structural damage. FEV1 is usually low in 
patients when there is considerable damage to the parenchyma of the lung.  
    
Bronchoscopy may be diagnostic or therpeutic. It can diagnose a bronchostenosis and 
help in retrieving a foreign body to clear the airway. . In cases of acute on chronic 
exacerbation, it can be used to obtain cultures for planning appropriate antibiotics. Broncho 
alveolar lavage helps in decreasing the bacterial load thus helping chronic patients who 
suddenly worsen (66). 
Diagnosis is arrived with proper history with HRCT and spirometry. Co-existent 
symptoms and age of presentation decides the necessity of further work-up like sweat-
chloride test to rule out cystic fibrosis, serum  immunoglobulin, perciptin antibody, or 
electron microscopy to look for ciliary related problems(67). 
 
Management 
There are myriad of management for Bronchiectasis but the ultimate goal of treatment 
should aim the following  
1) To limit the cycle of infection  
2) Prevent airway damage  
3) Improve symptomatology  
4) Reduce the exacerbations   
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5) Improve quality of life (54,57) 
 
 
 General supportive care 
                    General health measures like  maintaining good nutrition, avoiding smoking, 
regular exercises and breathing fresh air are considered general supportive measures for any 
pulmonary ailment patients(68). Management of this condition ideally should be team work 
including the physician ,thoracic surgeon, physiotherapist ,psychologist ,nurses and 
occupational therapist (68) . However there is no definite management protocol and it has to 
be tailored according to the individual patients. 
Management of underlying causes underlying causes 
Next step in the management is to identify the underlying treatable cause for the 
disease. Studies have shown that even if the underlying cause is identified it  may not alter 
the natural history of the disease (54). 
 
Methods to prevent secondary infection 
It is evident that in Bronchiectasis repeated infections play a vital role in the 
pathogenesis. In order to prevent the secondary infections especially in childhood appropriate 
vaccination may be used .There is no data in favour  or against the Influenza vaccination in 
both child and adult patients. But  general concept of this vaccination is that it will help in 
preventing  the acute exacerbations induced by this organism (59). In the same way, for the 
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23-valent pneumococcal vaccine also,  studies and extensive Cochrane database  review 
concluded  that there is no added advantage of vaccination. However, the  general concept is 
to administer this vaccine for both adult and children even if the advantage is minimal(69). 
 
Mobilisation of bronchial secretions 
It forms important part in the medical management as well as pre-operative 
preparation of the patients as it breaks the vicious cycle of the disease. Commonly used 
therapy techniques are: 
 1) High frequency percussion  
2) Positive expiratory  pressures  
 3) Active cycle of breathing exercises  
4) Postural drainage .  
All these exercises not only train the muscles but also help in increasing exercise 
capacity and in turn improve quality of life (70). 
Bronchodilators 
Although there is varying degree of airflow obstruction with airway hyper reactivity,  
bronchodilators are very useful. Many  studies are conducted in the past to find the effects of 
short-acting or long-acting beta-agonists, methylxanthines or short-acting anticholinergics  in 
the management of patients with Bronchiectasis(54,56,71–73). 
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Antibiotics 
Various studies has proven the usefulness of antibiotics during acute infective 
exacerbations  and during the maintenance phase(70).  The route of administration should be 
individualised to patient as either oral, parentral or inhalational. The choice of antibiotics 
should be directed by the sputum culture report. Generally, common organisms like P 
aeruginosa, H influenzae, and S aureus respond to broad spectrum antibiotics.  (74).  
Intravenous antibiotics should be reserved for sicker patients who are not responding to oral 
therapy.  
In one study, a 14-day course of intravenous antibiotics improved systemic 
symptoms, sputum volume, bacterial clearance, inflammatory markers and quality of life but 
not the pulmonary function as indicated by  FEV1 and FVC)(75). There is also substantial 
evidence in literature on the use of prolonged antibiotics in patients with Bronchiectasis, in 
particular with severe bronchial sepsis, and in cases not responding to conventional courses 
of antibiotics which   show meagre benefit with regard to symptoms, improved sputum 
parameters, decrease in inflammation, and improvement in lung function.  Hence it is 
recommended that if long-term antibiotics are to be used in Bronchiectasis, it should be 
confined to  the subset of patients with chronic bronchial sepsis who are not responding to 
conventional antibiotic therapy or in cases with frequent exacerbations. There is however, 
emerging evidence in support of  long-term macrolide therapy in patients with Bronchiectasis 
not responding to the usual regimen. Inhaled antibiotics for Bronchiectasis was investigated 
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extensively,  especially for pseudomonas infection with tobramycin and gentamycin,  but it 
was found out that it is successful in reducing the bacterial density only. 
 
 
Anti-inflammatory  treatment 
After extensive research, the two drugs considered important in the treatment of in 
Bronchiectasis are: 
1) Corticosteroids  
                        2) Macrolide antibiotics 
 
Corticosteroids 
It is used in patients with Bronchiectasis associated asthma, COPD, or airway hyper 
reactivity.  Many studies indicate that their  primary anti-inflammatory action is beneficial in 
the treatment of Bronchiectasis(76,77).   Though short term benefits are noted with high dose 
inhaled steroids, recent Cochrane review suggests that use of inhaled steroids either routinely 
or during exacerbations is not recommended(78).  
 
Macrolides antiobiotics 
Macrolides reduces airway infection and inflammation. Thus it reduces the volume of 
sputum and release of inflammatory markers as well. Its mechanism of action is 
multifactorial extending beyond its antimicrobial action. It has been identified to exert its 
action on the immune system making the host more sensitized to other pathogens. However 
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there is not much improvement in  the overall quality of life (79). They also have significant 
effect on mucociliary clearance which helps in clearing of the sputum (81).  
 Macrolide resistance is known and is more common in patients who have infection by 
Mycobacterium avium complex(80). 
Surgical management of Bronchiectasis 
In the past, surgical therapy was cornerstone in  treating  focal Bronchiectasis. In 
modern antibiotic era with effective drug therapy and supportive treatment, ,surgery has 
become much less common (81). However, patients with refractory symptoms in spite of 
excellent medical management may benefit from resection of a localized bronchiectatic 
segment or lobe. Before embarking on surgery, a uncorrectable predisposing factor like 
ciliary dysmotility should be excluded especially in patients with multifocal disease.  
 
The CT scan should be critically reviewed and other supportive investigations should 
be reconfirmed before making a final decision about resection to ensure that there is no 
multifocal involvement. The surgery is    planned to preserve as much normal Parenchyma as 
possible at the same time not to retain potentially infective foci of parenchyma which will 
make the patient symptomatic soon after an incomplete resection. 
 
There are studies to prove that lung resection is beneficial in Bronchiectasis both in 
children as well as in adults. Aggressive medical and physical therapy are recommended 
before surgery is contemplated. 
 Specific indications for surgery are:   
 
(1) Haemoptysis –recurrent episodes of small bouts or single life threatening episode , 
            (2) Localized disease which doesn’t respond to medical treatment                                     
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            (3) Persisting symptoms  
            (4) Resectable disease causing persistent foci of infection                 
            (5) Resectable disease with failure to thrive. 
       
 Although there are numerous studies published comparing the clinical experience 
with various surgical techniques in the management of Bronchiectasis it is the decision of the  
individual thoracic surgeon  to decide about the operability and to redefine the indications 
according to the patient’s need(81–87). The Cochrane review indicated that there were no 
randomized or controlled trials  which compares surgery with nonsurgical treatment for 
Bronchiectasis (88).  
 
Until 1970`s physicians believed bilateral or multi segmental  Bronchiectasis was 
considered  as contraindication for surgical treatment (89) due to the poor results (90).. After 
1970, the thoracic surgeons came up with the concept that bilateral disease is not a 
contraindication for surgery since the results had increased.   (90). Surgery should be reserved 
for patients in whom curative resection can be achieved and these are usually cases of 
localized cystic unilateral Bronchiectasis. The indication can also be extended to bilateral 
localized Bronchiectasis or completely destroyed lungs provided the residual respiratory 
function is good. Resection of localized cystic bronchiectasis in the presence of scattered 
cylindrical bronchiectasis can improve symptoms and quality of life with low operative 
morbidity.  
 
Surgical intervention is considered in patients with massive haemoptysis that 
originates from hypertrophied bronchial arteries. However, it is necessary to recognize that 
surgical resection should be considered only in a patient with sufficient pulmonary reserve. 
Embolization of bronchial artery, even with its high rates of recurrence, is an excellent 
alternative tool for emergency surgery for massive haemoptysis now a days.. The surgical 
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technique for resection is difficult to standardize but the ultimate goal for the surgeon should 
be, to preserve as much as lung possible. Lung Transplantation is an option for patients who 
are seriously compromised in pulmonary function and chronic respiratory failure. 
 
Results and Observation 
 
In our study there were   242 patients out of which  155 (64%) are male remaining 87(36%) 
were female. 
Figure-1 
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AGE 
The mean age of presentation for surgery is 34 years , youngest was 12 years  old and 
the oldest  66 years. 
Table-1 
Variable n Mean S.D. Minimum Median Maximum 
       Age 241 34.19 11.83 12 33 66 
It is observed that majority of our patients belong to second and third decade of life. 
Figure-2 
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Presenting symptoms 
The most common complaint at presentation was Haemoptysis (45%) followed by 
copious expectorations (40%). Fifteen percentage of them had both symptoms.  
 
Figure-3 
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Duration of symptoms 
The  average duration of symptoms at presentation was  5.5 years .  The duration of 
symptoms ranged from 1 month to 34 years.  
 
Distribution of the disease 
40% 
45% 
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Presenting Symptom 
Cough with expectoration 
Hemoptysis 
Both 
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It is found that majority of the patients had Bronchiectasis on the left side 56%, 33% 
had disease only on right side. About 11 % of patients had bilateral disease. Most patients had 
bilateral minor disease as evident in HRCT. 
 
Figure -4   
 
 
 
Medical treatment history 
Seventy three percentage of percentage the patients had been treated with  short or 
long term antibiotics repeatedly, 63% of them  were on oral or inhaled bronchodilators along 
with antibiotics. Nearly 58% of the people had taken anti-tuberculous treatment (ATT). 
Figure-5 
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The average duration of medical treatment before being referred for  surgery is 4 years in our 
series.  
 
 
 
 
Investigations  
All the patients in our series underwent chest x-ray  and in 65% of the patients, the 
diagnosis was made with just the x-ray. . 
 
Figure-6 
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Medical Treatment History  
Medical Treatment History  
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High Resolution Computed tomography (HRCT) findings 
HRCT showed features favouring Bronchiectasis only in 93% of patients. It is also 
helpful in identifying completely destroyed lungs (11%), pleural effusion  ( 2%),  unrelated 
mass lesions (1%) and miscellaneous findings in 7% of patients. 
 
Figure-7 
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Pulmonary function test (PFT) 
PFT was done in all patients prior to surgery. In 56% of patients it is restrictive and 
the remaining 44% it showed obstructive pattern. 
 
Figure-8 
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The  average FEV1 in our series is 1.96L, FEV1/FVC ratio is 87.5%.  Most of our patients 
had restrictive pulmonary function test. 
 
 
Sputum culture 
Sputum was positive in 57% of the patients only. 
 
Figure-9 
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 A mixture of organisms were seen in half the patients. Hemophilus influenza was isolated  in 
26% of them,   Pseudomonas species in 18% and Strep.pneumoniae in the rest.                                      
 
 
 
Figure-10 
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                     Split up of specific organisms isolated 
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All the patients were subjected to bronchoscopy.  12 patients (0.05%) were identified 
to have significant bronchial stenosis.  Seven of the setenosis were on the left and  five were 
on the right side.  
 
Figure-11 
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The most common indication was haemotpysis in 48%  then  cough with copious 
expectoration  in 46%  of patients, both  in  13% of the patients.  
 
Figure-12 
 
 
2% of our patients (5 patients) had undergone previous surgery and presented this time with 
persistent symptoms or worsening symptoms which required revision surgery.  
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The majority of the patient had either single Lobectomy (54.5%),bilobectomy(16%) 
or pneumonectomy (23%). In a small number of patients segmentectomy was done (6 
patients). Lobectomy along with segmentecomy was done in 10 patients. 
 
Figure-13 
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There were 39 patients who had complications which accounts for 16% of the total 
patients in our series.   
Out of these patients 15 of them had empyema post-operatively, 12 patients had 
prolonged air leak, 2 patients had Bronchopleural fistula, 2 patients had immediate post 
operative bleeding, and 1 patient had atelectasis. There were  2 mortality. 
       Table-2 
S.No complication No of patients 
1. Empyema 15 
2. Prolonged air leak 12 
3. Infection 7 
4. Bronchopleural fistula 2 
5. Immediate post-op bleeding 2 
6. Post-op atlectasis 1 
7. Mortality 2 
 
 
 
 
 
 
Figure-14 
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The  post-operative management of the complications were one of the following like 
Re-thoracotomy for bleeding, BPF closure, Intercostal drainage  and window procedure . 
         Table-3 
S.No Complications  No of patients 
1. BPF closure 2 
2. ICD insertion 12 
3. Re –thoracotomy 2 
4. Window procedure 7 
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Complete resection of diseased portions of the lung was achieved in  in 85% of the 
people and  15% of the had residual disease elsewhere. 
Figure-15 
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In the follow up period after surgery 76% were completely asymptomatic, 12% had 
residual minor symptoms. 12% of our patient did not have a proper follow up.  
The average follow up of our patients is 5.1 years  (range from 1 month to 13 years) 
Figure-16 
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Analysis of symptomatic and asymptomatic patients post-operatively 
The variables were calculated using chi-square test. 
The  p-value <0.05 indicates a significant association between outcome and other variables 
     Table-4 
variables group 
Asymptomatic Symptomatic 
p-val n % n % 
symptom purulent sputum 36 26.67 7 24.14 
0.92  
haemoptysis 46 34.07 11 37.93 
 
both 53 39.26 11 37.93 
 
It is observed from our study that the mode of presentation like purulent sputum or 
haemoptysis has no statistically significant association p value is >0.05  
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Figure-17
 
 
Association between procedure done and outcome 
The various procedures done for the treatment and the outcome after surgery appears 
not associated  in our study as the p value is 0.97 
Table-5 
variables group 
asymptomatic symptomatic 
p-val n % n % 
procedure 
     
0.97 
 
Lobectomy 94 71.76 21 72.41 
 
Pneumonectomy 29 22.14 6 20.69 
 
Segmentectomy+segmentecto
my with lobectomy 8 6.11 2 6.90 
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The following bar diagram depicts the procedure done to outcome of the 
patient 
Figure-18 
 
 
Association between sputum culture positivity and post operative 
symptoms 
Table-6 
variables group 
asymptomatic symptomatic 
p-val n % n % 
sputum 
culture positive 51 51 13 81.25 
0.024 
 
Negative 49 49 3 18.75 
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 It is observed that patients with significant bacterial infection as per cultures  pre 
operatively, continued to have some symptoms post operatively also even after successful 
resection. (p value  0.024). It is shown in the following diagram 
 
Figure-19 
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Association between PFT and outcome 
In patients with evidence of obstructive disease in PFT were more often symptomatic 
even after surgery  (p value 0.005). Thus there is a strong association between the pre-
operative state of the lung or the pulmonary reserve and the outcome after surgery. 
Table-7 
variables group 
asymptomatic symptomatic 
p-val n % n % 
PFT Restrictive 76 64.41 8 33.33 
0.005 
 
Obstructive 42 35.59 16 66.67 
 
 The association between the PFT and the outcome is shown in the following figure 
Figure-20 
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Association between completeness of resection and outcome 
Patients in who complete resection was possible had no post operative symptoms  as 
opposed to those who had residual disease after resection who remained partially 
symptomatic. This association was statistically significant.  
 
Table-8 
variables group 
asymptomatic symptomatic 
p-val n % n % 
Follow up 
Complete 
eradication  50 100 4 14.29 
<0.001 
 
Incomplete 
eradication 0 0 24 85.71 
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Figure-21 
The above figure shows the significant association between the resection of the 
disease and outcome. 
 
Association between outcome and residual Bronchiectasis 
Table-9 
variables group 
asymptomatic symptomatic 
p-val n % n % 
       Residual 
Bronchiectasis No 135 100 2 6.9 
<0.001 
 
Yes 0 0 27 93.1 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Complete Resection Incomplete resection 
Asymptomatic 
Symptomatic 
 64 
 
 
It is evident from the above table that presence of residual disease is single most 
important factor which accounts for 93% of symptomatic patients. From the p value <0.001 it 
is clearly proved that this variable is strongly associated with the outcome. 
     
The following diagram shows the association between the variable and outcome. 
Figure-22
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Discussion 
  Bronchiectasis is a chronic condition characterised by abnormal dilatation of the 
affected bronchi.  Before the antibiotic era it was a dreadful disease resulting in significant 
number of patients landing in respiratory failure and cor pulmonale. The exact prevalence of 
the disease was difficult to ascertain. 
We analysed 242 patients   retrospectively who underwent surgical treatment for 
Bronchiectasis between 1992 - 2012. All the patients who were operated upon were included 
in the study and those patients who were not fit for surgery of those who refused surgery 
were excluded from the study.  
 Out of the 242 patients analysed, majority of them were males ( 64%)  while the 
remaining 36% were females (figure-1). This increased incidence in males is noted in most of 
the other series like Balkanli et al, cayalak et al. However,  kutlay et al found higher 
incidence in females(55%). This higher incidence among men  may be due to the higher 
prevelance of smoking and substance abuse among men in our country,    The availability of 
over the counter drugs for cough and expectoration and  delay in seeking medical attention 
are also factors that are responsible for  the increased incidence in males who are the bread 
winners of the family and thus do not have the time or  money to spend on doctors.. 
In our series the minimum age of the patient who underwent surgery is 12 years old , 
with maximum we operated on a 66 year old patient(figure-2). The median age is 34 
years(table-1). It is observed that majority of our patients were between the age group        
20-40(figure-2).The median age of the patient was same as observed in kutlay et al  
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In our study group majority of the patients presented with Haemoptysis (45%). 
Chronic cough with expectoration was present in 40% of our patients. However 14% of the 
patients had both Haemoptysis and expectoration.  
Reda Alfaei et al, Kutlay et al, found that  recurrent  infections with expectoration of 
copious foul smelling sputum  was the common presenting symptom. In India, haemoptysis, 
being a more alarming symptom makes the patient seek medical attention rather than the 
copious expectoration which is often a neglected symptom for reasons mentioned earlier.  
Duration of symptoms before surgery had a wide range from as less as to 1 month to 
as long as 34 years in a patient. The average duration of our patients is 5.5 years. In Kutlay et 
al the mean age is 5.7 years which is similar to our study. This long duration of the symptoms 
is primarily due to long indolent nature of the disease. Only the presence of a streak of  
haemoptysis, makes the patient opt for  surgery.  
The improvement in the standard of medical care including availability of  inhaled  
macrolides, use of steroids etc  has delayed or decreased the number of patients requiring 
surgery.  
Like other studies majority of our patients (56%)  had disease involving the  left side 
only, 33%  had disease  on the right side only  on right and 11% had bilateral disease.  
Gravity makes the  purulent secretions pool in the  the lower lobes,  making  them 
more prone for the development of Bronchiectasis.  The incidence is higher on the left side as 
compared to the right  since  the left main bronchus is a more acute angle to the  midline than 
the right. Thus the mucociliary clearance is better in the right lung.   
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The left main bronchus is narrower and longer than the right  making it more 
vulnerable to blockage, due to enlarged  peribronchial lymph nodes or viscid sputum.  
However, foreign body aspirations are more common on the right side 
In a study by Caylak et al,  66% of the patients had left sided disease which is more 
than our series.  However in most  studies like in the series by Kutlay et al, King PT et al, the 
side incidence is  similar to that in  our study.  
 Middle lobe is more  frequently affected because of its long and slender with  acute 
normal angulations, prone to being compressed by  enlarged lymph nodes. 
About two thirds of our patients (73%) was taking antibiotics regularly as prolonged 
short courses (>14 days) or long term antibiotics (> 6 weeks) to control  repeated chest 
infection. Along with antibiotics about 63% of the patients were on bronchodilators. In our 
series 58 % of them had taken  Anti-Tuberculous medicines. The incidence of ATT is slightly 
higher when compared to western studies probably because of the higher prevalence of 
Tuberculosis in our community and the arbitrary usage of these medications without proper 
confirmation of tuberculosis.  Average duration of medical therapy before surgery is 4 years 
which is similar to the study  done by Kutlay et al. Maximum duration of medical therapy in 
our series is 15 years. 
With regards to  investigations,  plain chest X-ray alone was diagnostic of 
Bronchiectasis in 64%. This incidence is  higher when compared to other studies like 
Balkalni et al, Kutlay et al. The reason for this increased sensitivity of X-ray may be the 
delayed presentation of the patients where the features are obvious for diagnosing even in    
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x-ray. In western literature, perhaps due to early presentations, the  chest X-ray is less 
sensitive.  
About 16% of our patients had typical features like multiple cysts with  air fluid levels 
suggestive of Bronchiectasis. Such a picture in chest X-ray will appear only late in the course 
of the disease. In our study group about 15% had features like consolidation in chest X-ray. 
Localized Bronchiectasis confined to single lobe may appear as mass lesion in X-ray a 
finding in about  5% of our patient.   However, the  reliability of the chest x-ray as a 
diagnostic tool  is not good and a HRCT is mandatory for accurate diagnosis especially 
before subjecting any patient for surgery. . 
Thus an high resolution computed tomography (HRCT) is the imaging modality of 
choice for investigating a case of Bronchiectasis. In our series 93% of the people had features 
suggestive of Bronchiectasis without much diagnostic dilemma. In addition to the diagnosis 
of bronchiectasis, it can pick up other co-existing pathology. A completely destroyed lung 
was seen in 11% of the patients,  concomitant pleural effusion in 2%, and co-existing 
neoplasm was diagnosed in less than 1 % (3 patients). 
    Pulmonary function testing (PFT) was carried out in all the patient undergoing 
surgery. It showed obstructive pathology in 56% and restrictive pathology in  44%. The 
higher number of patients with obstructive pathology may be due to co- existent COPD.  
More patients with  obstructive pathology in PFT had  residual symptoms post operatively 
than those with restrictive pathology  in PFT pre operatively. This finding was statistically 
significant ( p value 0.005). Hence the pulmonary reserve of the individual as well as the 
baseline PFT has significant impact on the outcome. 
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All the patients had sputum cultures done. In our study group we found that 57% of 
the people showed positive sputum cultures whereas only 43% showed no growth. This is on 
par with other studies like King PT et al where the sputum positivity was 62%. In those who 
have sputum positivity,  a mixed growth of organisms were isolated in 50% (figure-10) and 
specific  organisms  were isolated in the remaining 50%. Among the organisms isolated in 
our group,  H.influenzae accounted for 26%, followed by Pseudomonas in 18% and  Strep. 
pneumonia 6%. Other studies like Angrill et al has shown Pseudomonas as the principle 
respiratory isolate in their series. In patients with immunocompromised state also,  the 
primary isolate was pseudomonas. In Kutlay et al like our study the most common organism 
isolated was H.influenzae. Presence of pre operative infection in the sputum had an direct  
correlation to the  persistence of symptoms post operatively (p value 0.024)  Bronchoscopy 
was done in all patients undergoing surgery. The primary aim of bronchoscopy was to rule 
out any foreign body associated  with the Bronchiectasis,  associated bronchialstenosis or 
intra luminal or extrinsic compression . We had 12 patients (0.05%) who had significant 
findings in the bronchoscopy (figure-11). A bronchoalveolar lavage was also useful in 
initating the appropriate antibiotic. 
The main indication for surgery in our group is a  history of repeated cough with 
expectoration (48%) followed by  haemoptysis accounting for 48% of the patients operated. 
The common indication in other studies were repeated infections  as per Bagerhi et al 
(77.1%) and Reda alfaie et al (71.7%). When compared to these  studies this indication for 
surgery in our series is less. 
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Haemoptysis is the other significant indication in our study (48%) which, when 
compared to Reda alfaie et al (15.9%) is almost triple the number. (figure-12). 
   The commonest surgery  done in our study is single lobectomy (54.5%), followed by 
pneumonectomy (23%). Zhang p et al while analysing a group of 790 patients found  
lobectomy(72%) to the commonest.  In Bagheri et al the lobectomy was done only in 42%, 
less than in our series. Its obvious that  that lobectomy is the procedure of choice when the 
disease is confined of localised to a lobe. More aggressive removal of lobe when it is not 
macroscopically diseased is not advised in the literature. For disease involving more than two 
lobes with CT evidence of disease in the third lobe , pneumonectomy may be considered in 
order to prevent relapse of symptoms earlier. When the disease was localised to a small 
segment or lingula alone then a segmentectomy or a  lingulectomy is warranted. . 
 39 patients   (16%) who underwent surgery had post operative complications. 
Commonest complication in our series was post operative empyema in 15 patients(0.06%), 
prolonged air leak in 12 patients (0.05%), post operative infection in 7 patients, 
bronchopleural fistula in 2 patients, atelectasis in 1 patient and immediate post-operative 
bleeding in 2 which required re-thoracotomy  for controlling it.  
When compared to Hiramatsu et al  (18%) , the overall complication rate in our 
group(16%) is slightly less. The complication rate (16%) is on par with Bagheri et al (15.8%). 
The infection rate in our series (2.8%) is less when compared to Bagheri et al (5.7%). There 
mortality in our series is 0.8%(2 patients) which is comparable to  other series  like Bagheri et 
al  and Zhang p et al. The post-operative complication management included BPF closure in 
2 patients, window procedure in 7 patients and re-exploration for bleeding in 2 patients. 
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In our series, complete resection of the macroscopic disease was done in 85% of 
patients. In 15% of the patients there was  residual disease elsewhere in the lung .Partial   
resection of the disease included bilateral disease in which unilateral lobectomy done, 
minimal disease in the other lobes as evidenced by CT but macroscopically healthy looking 
lobes. When compared to Reda Alfaie et al (94%) the complete resection rates in our series is 
low. The incomplete resection group had a statistically significant symptoms after surgery (p 
value <0.001). 
  The outcome of our study is based on whether patient is free of symptom or is the 
patient symptomatic after the surgery.  Univariate analysis of this variable was done using chi 
square test, a p value of less than 0.05 is considered significant association. 
It is statistically proven that the presenting symptoms like purulent sputum, 
haemoptysis is not associated with the outcome (, p value  0.92). Similarly in our  series the 
procedure done whether it is  lobectomy,pneumonectomy or segmentectomy did not show 
statistical significance  with regards to post operative symptoms (p value 0.97).  
However the presence of a positive culture pre operatively was associated with 
persistence of  post  operative symptoms.  (p value 0.024). In the patient with persistence 
symptoms post operatively,  81% of the people had sputum positivity.  
An obstructive PFT affected the post operative symptoms (p value0.005).   67% of the 
patients who were symptomatic post operatively had  obstructive pathology in PFT pre 
operatively. 
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The extent  of surgical resection whether complete  or incomplete   has a strong 
statistical significance to the outcome, p value being <0.001.  It is noted that 86% of the 
patients who were symptomatic after surgery had  residual minor disease elsewhere in lung. .       
In our group 93% of the patients who were symptomatic after surgery had had residual 
Bronchiectasis. 
76% of our patients, as comparable to  Dogan et al (80%) were totally  asymptomatic 
after resection. Compared to Bagheri et al (58%) the patients in our series has a better 
symptomfree life after surgery.   
Sequential resection for bilateral disease could be planned about 6 weeks apart. Two 
of our patients had  had thoracotomy and resection on the opposite side for removal of a  
diseased segment. 
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Conclusion 
Bronchiectasis is primarily a medical disease which requires careful assessment and 
diagnosis. Once diagnosis is made, the patient should be under medical surveillance and 
treatment for repeated infections and haemoptysis.  Appropriate antibiotics as dictated by 
cultures should be initiated in order to avoid progression of the disease. If and when surgery 
is indicated, a  thorough pre-operative evaluation should be carried out.    As in other 
literature, our study also proves that surgical treatment for Bronchiectasis can be done safely 
with minimal acceptable mortality and morbidity. Single most important factor which decides 
on the symptom free state after surgery is the adequacy of the resection. Complete resection 
of the localised Bronchiectasis offers better cure as well as symptom free survival after 
surgery. However it should be appreciated that in cases of diffuse bilateral disease,  post 
operative residual Bronchiectasis is unavoidable. In such cases, though the intensity of 
symptoms may improve greatly after surgery, minimal  symptoms may persist.   
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